Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with cyclophosphamide in multiple sclerosis: the cons.

W H Likosky1

  • 1Kaiser Permanente Medical Care Program, Santa Clara, CA 95051.

Neurology
|July 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED].

Neurology·2002
Same author

Implementation of a hospitalist system in a large health maintenance organization: the Kaiser Permanente experience.

Annals of internal medicine·1999
Same author

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.

Journal of neurology, neurosurgery, and psychiatry·1991
Same author

Comprehensive viral immunology of multiple sclerosis. II. Analysis of serum and CSF antibodies by standard serologic methods.

Archives of neurology·1980
Same author

Comprehensive viral immunology of multiple sclerosis. III. Analysis of CSF antibodies by radioimmunoassay.

Archives of neurology·1980
Same author

Comprehensive viral immunology of multiple sclerosis. I. Clinical, epidemiological, and CSF studies.

Archives of neurology·1980
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

Cyclophosphamide treatment for chronic progressive multiple sclerosis (MS) shows potential safety in outpatient settings, but substantial benefits are unlikely. Further research is needed to confirm efficacy due to study limitations.

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple Sclerosis (MS) is a chronic, progressive neurological disease.
  • Immunosuppressive therapies are explored for managing MS.
  • Cyclophosphamide has been investigated for its potential effects on MS.

Purpose of the Study:

  • To evaluate the utility of intensive immunosuppression with cyclophosphamide versus folic acid in chronic progressive multiple sclerosis (MS).

Main Methods:

  • A study involving 44 patients with chronic progressive MS.
  • Comparison of cyclophosphamide treatment against folic acid.
  • Administration of cyclophosphamide in an outpatient clinic setting.

Main Results:

  • Preliminary data suggest cyclophosphamide can be safely administered in an outpatient setting.

Related Experiment Videos

  • Modest benefits of cyclophosphamide cannot be ruled out.
  • Substantial benefits of cyclophosphamide therapy are considered doubtful.

    • Conclusions:

    • The hypothesis of a favorable effect of cyclophosphamide on the course of MS is considered weak.
    • Previous studies supporting cyclophosphamide's efficacy in MS often have design shortcomings.
    • Further rigorous studies are needed to ascertain the true impact of cyclophosphamide on MS progression.